文献速递冠心病血脂与心血管预防

阿利西尤单抗对近期急性冠脉综合征患者主要不良心血管事件的影响:ODYSSEY OUTCOMES 随机临床试验按肾功能预设分析

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
PubMed 文献 · Eur Heart J · 2020-01-01

ODYSSEY OUTCOMES 预设分析纳入 18 918 例近期急性冠脉综合征且接受强化他汀治疗的患者,评估阿利西尤单抗疗效是否受肾功能影响。结果显示,阿利西尤单抗在研究的肾功能范围内与更少心血管事件和死亡相关,eGFR≥60 mL/min/1.73 m² 者相对风险降低更明显,eGFR<60 者未观察到显著获益。

要点

  • 阿利西尤单抗在 eGFR≥90 和 60–<90 亚组显著降低主要终点,eGFR<60 亚组未显著。
  • 连续 eGFR 与治疗对主要终点和死亡无交互作用(P=0.14 和 0.59)。
  • 除局部注射部位反应外,各 eGFR 类别不良事件两组相似。

核心结论

  • 在近期急性冠脉综合征患者中,阿利西尤单抗在研究肾功能范围内与更少心血管事件和死亡相关。
  • eGFR>60 mL/min/1.73 m² 者相对风险降低幅度更大,eGFR<60 者未观察到显著获益。

研究设计与样本

  • ODYSSEY OUTCOMES 随机临床试验的预设分析,比较阿利西尤单抗与安慰剂。
  • 纳入 18 918 例近期急性冠脉综合征且强化他汀治疗下仍存在血脂异常的患者,eGFR<30 mL/min/1.73 m² 被排除。
  • 基线 eGFR 为 82.8 ± 17.6 mL/min/1.73 m²,LDL-C 为 92 ± 31 mg/dL。

主要发现

  • 36 个月时,阿利西尤单抗较安慰剂降低 LDL-C 48.5%,未影响 eGFR(P=0.65)。
  • 连续 eGFR 与治疗对主要终点和死亡无交互作用(P=0.14 和 0.59)。
  • eGFR≥90 mL/min/1.73 m² 亚组(n=7470)主要终点风险比 0.784(95%CI 0.670-0.919;P=0.003)。
  • eGFR 60–<90 mL/min/1.73 m² 亚组(n=9326)主要终点风险比 0.833(95%CI 0.731-0.949;P=0.006)。
  • eGFR<60 mL/min/1.73 m² 亚组(n=2122)主要终点风险比 0.974(95%CI 0.805-1.178;P=0.784)。

临床怎么用

  • 对近期急性冠脉综合征且 eGFR≥60 mL/min/1.73 m² 的患者,阿利西尤单抗可显著降低主要不良心血管事件风险。
  • eGFR<60 mL/min/1.73 m² 患者使用阿利西尤单抗未显示显著心血管获益,但不良事件与安慰剂相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined whether effects of the PCSK9 inhibitor alirocumab to reduce cardiovascular events and death after ACS are influenced by renal function. METHODS AND RESULTS: ODYSSEY OUTCOMES compared alirocumab with placebo in patients with recent ACS and dyslipidaemia despite intensive statin treatment. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 was exclusionary. In 18 918 patients, baseline eGFR was 82.8 ± 17.6 mL/min/1.73 m2, and low-density lipoprotein cholesterol (LDL-C) was 92 ± 31 mg/dL. At 36 months, alirocumab decreased LDL-C by 48.5% vs. placebo but did not affect eGFR (P = 0.65). Overall, alirocumab reduced risk of the primary outcome (coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization) with fewer deaths. There was no interaction between continuous eGFR and treatment on the primary outcome or death (P = 0.14 and 0.59, respectively). Alirocumab reduced primary outcomes in patients with eGFR ≥90 mL/min/1.73 m2 (n = 7470; hazard ratio 0.784, 95% confidence interval 0.670-0.919; P = 0.003) and 60 to <90 (n = 9326; 0.833, 0.731-0.949; P = 0.006), but not in those with eGFR < 60 (n = 2122; 0.974, 0.805-1.178; P = 0.784). Adverse events other than local injection-site reactions were similar in both groups across all categories of eGFR. CONCLUSIONS: In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tuñón J, Steg PG, Bhatt DL, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020. PMID: 32820320. doi:10.1093/eurheartj/ehaa498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。